SCHEMBL3596985

SCHEMBL3596985

O=[N+]([O-])c1ccc2c(C(O)(CN3CCS(=O)(=O)CC3)C(F)(F)F)cn(Cc3ccccc3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
CYP2C9 P11712 1/20 0.40
CACNB4 O00305 1/20 0.37
CACNA1A O00555 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNG3 O60359 1/20 0.37
CACNA1F O60840 1/20 0.37
CACNA1H O95180 1/20 0.37
CACNB3 P54284 1/20 0.37
CACNA2D1 P54289 1/20 0.37
CACNG7 P62955 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNA1D Q01668 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3596984 0.93 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MAPTCYP2D6CYP2C19
SCHEMBL3596986 0.93 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MAPTCYP2D6CYP2C19
SCHEMBL3594430 0.91 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTCYP2D6CYP2C19
SCHEMBL3595274 0.90 HTR7 (0.39) ALDH1A1SMN1; SMN2MAPTCYP2D6CYP2C19
SCHEMBL3597934 0.90 CACNB4 (0.44) ALDH1A1SMN1; SMN2MAPTCACNB4CACNA1A
SCHEMBL3598200 0.89 KAT2B (0.38) ALDH1A1SMN1; SMN2MAPTCACNB4CACNA1A
SCHEMBL13254029 0.89 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2MAPTCACNB4CACNA1A
SCHEMBL3600408 0.89 KCNJ1 (0.47) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C19
Hydrochloric Acid SCHEMBL3593801 0.88 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2MAPTCACNB4CACNA1A
SCHEMBL3586986 0.88 KDM4E (0.43) ALDH1A1MAPTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 ALDH1A1 4118/4885SMN1; SMN2 4722/4885MAPT 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.